Objectives To determine the effects of atenolol, nifedipine and their combination on exercise parameters and ambulatory ischaemic activity in patients with mild chronic stable angina.
Introduction
Many reports have testified to the effective antiischaemic and anti-anginal actions of the medical therapies at our disposal for the treatment of patients with stable angina' 1 " 31 . However, few studies have assessed the potential prognostic significance of such therapies for these patients. While it is known that beta-adrenergic blocking agents are of prognostic benefit in the postmyocardial infarction setting 14 ' 51 , there is little evidence to demonstrate prognostic benefit from the use of betablockers or calcium antagonists in the setting of stable angina. Certain subgroups of patients with severe coronary artery disease have been shown to benefit prognostically, at least in the medium term, from coronary artery bypass surgery 16 -71 , though the prognostic benefit of surgery in mild angina is unclear. Further, there is Submitted 22 November 1994, and accepted 22 February 1995. Correspondence Dr K. M. Fox, Royal Brompton Hospital, Sydney Street, London SW3 6NP, U.K. no evidence that modification of the total ischaemic burden by medical therapy results in an improved outlook for the patient with stable angina' 81 , and indeed there is conflicting evidence about the significance of such episodes of transient ischaemia during daily life for subsequent outcome in stable angina patients' 9 -101 . The TIBET (Total Ischaemic Burden European Trial), is a major European multicentre double-blind parallel-group trial designed to determine whether the total ischaemic burden has important prognostic implications in patients with stable angina on standard anti-anginal treatments, and whether one form of antianginal therapy offers greater prognostic benefit over another, or if combination therapy is of additive prognostic benefit when compared with monotherapy. A secondary objective was to assess the anti-ischaemic effects of atenolol, nifedipine SR, and their combination, using standardized exercise testing and ambulatory ST segment monitoring. This report focuses on the secondary end-points of the TIBET, which assessed the effects of the different medical therapies on the total ischaemic burden.
Patients and methods
The design, methodology and management of the TIBET have been previously reported 111] ; however, an overview is detailed below.
Patient selection
Patients of both sexes aged 40-79 years with stable angina (minimum of 3 months) who were not being considered for intervention, and who had objective evidence of ischaemia on exercise testing after a 2-week washout period were considered for study. Patients who had developed recurrent angina following previous coronary artery bypass surgery or percutaneous transluminal coronary angioplasty were also suitable for inclusion, as were those who were asymptomatic on medical therapy. Patients with recent myocardial infarction or intervention (<3 months), contra-indications to either of the study medications, conduction disturbances or medications likely to effect the interpretation of the ST segment were excluded.
Study design
The study was a double-blind, parallel-group comparison of twice-daily randomized treatment with atenolol 50 mg bd, nifedipine slow-release 20 mg bd or their combination, with a one month single-blind run-in period consisting of 2 weeks active combination treatment (to confirm that patients could tolerate the combination) followed by 2 weeks placebo treatment. Baseline measurements (exercise testing and 48 h ambulatory ST segment monitoring) were undertaken on placebo immediately prior to randomization. Exercise testing was repeated 2 and 6 weeks after randomization, whereas ambulatory ST segment monitoring was repeated 6 weeks after randomization. Resting heart rate and blood pressure were also documented at each visit.
For the purposes of assessment of the secondary end-points, a comparison of the measurements made on placebo immediately prior to randomization and on maximal therapy 6 weeks after is presented.
Exercise testing
All patients underwent maximal symptom-limited exercise testing at the end of the placebo phase immediately prior to randomization, and after 2 and 6 weeks of randomized, therapy using either a treadmill (Bruce) protocol or a bicycle protocol. Exercise testing was performed between 2 and 6 h post-dose, and at least 2 h post-prandial. The bicycle protocol commenced at 30 W and increased by 30 W every 3 min. Electrocardiograms were recorded at rest and every 3 min during exercise, and whenever chest pain, hypotension, or significant ST segment change developed. A test was considered positive if there was ST segment depression of >1 mm which was planar or downsloping and persisted for 0-08 s after the J point. Chest pain, dyspnoea, hypotension, exhaustion, or complex ventricular arrhythmias were indications for stopping test. Exercise testing analysis was performed in each case at a central monitoring site (Western Infirmary Hospital, Glasgow, U.K.).
Ambulatory st segment monitoring
Patients underwent 48 h of ambulatory ST segment monitoring at the end of the placebo phase immediately prior to randomization and after 6 weeks of randomized therapy. Monitoring was performed using pre-gelled electrodes to record two bipolar leads, an anterior CM 5 and an inferior lead. Sites and methods of application have been previously described 1 " 1 . Two-channel recordings were then obtained on magnetic tape by an Amplitude Modulated dual-channel recorder (Reynolds Tracker). Tapes were visually analysed at 60-120 times normal speed using the Reynolds Pathfinder 111 analyser, and all printouts were at 25mm. s~'. In addition to visual analysis, an ST segment trend was produced in each case. Significant ST segment depression was defined as a planar or downsloping shift of > 1 mm measured 008 after the J point, and persisting for > 1 min. Changes in T wave vector were not regarded as evidence of ischaemia unless they were accompanied by significant ST segment changes. All analyses of monitoring tapes were performed at a central monitoring site (Royal Brompton National Heart and Lung Hospital, London, U.K.).
During the periods of ambulatory ST segment monitoring all patients were encouraged to continue with their normal daily activities, which were performed outside the hospital environment.
Compliance and symptom assessment
Adherence to the dosage regimen was assessed by returned capsule counts, starting from the end of the run-in period with the combination, and from assay of drug metabolite levels in urine after 6 weeks of active randomized treatment. Patients were interviewed after 6 weeks of randomized treatment to establish whether symptoms had improved, stayed stable, or worsened. In addition, the number of patients who had 'dropped out' or had died in the intervening period was recorded.
Statistical analysis
Categorical variables (such as gender) were tabulated as frequencies and compared among treatment groups using chi-squared tests. Continuous variables (such as heart rate) were tabulated as mean (standard deviation) for baseline characteristics and mean (standard error of 
Results
Nine hundred and sixteen patients were recruited into the study, 682 (74-4%) eventually being randomized. The patients were drawn from 69 centres in nine European countries. In practice only 608 subjects (66-3%) (205 on atenolol, 202 on nifedipine SR, and 201 on the combination) satisfied the entry criterion of a valid exercise test with 1 0 mm ST segment depression on exercise at baseline on central analysis, and study of these 608 subjects form the basis of this report. Table 1 details the demographic data of the study population. Mean age was 60 years, 86% being males. Thirty-three percent had suffered a previous myocardial infarction; 21% were hypertensive, and 27% had prior documented coronary artery disease by angiography. The three treatment groups were generally well balanced for these variables. the mean) for changes from baseline on treatment.
Means were compared using one-way analysis of variance (ANOVA). Improvement from baseline within each treatment group was assessed by paired t-tests.
Censored variables such as 'time to pain' and 'time to 1 mm ST segment depression' were compared among treatments using two approaches. Firstly, in cases where the event concerned (i.e. pain or 1 mm ST segment depression) did not occur prior to the end of the test, total exercise time was substituted for the event time, data then being compared using one-way ANOVA. In the second approach, the data were treated as possibly censored survival times and compared using the log-rank test. The data were displayed graphically for each treatment group using the Kaplan-Meier estimator of the 'time to event' survival curves.
Because performances on the treadmill and bicycle exercise tests were different, these data have been analysed separately.
Improvement from baseline on ST segment monitoring within each treatment group was analysed using McNemars test. The distribution of changes from baseline in number of episodes of ischaemia and total duration of ischaemia were compared among treatments using a non-parametric (Kruskal-Wallis) test.
Baseline data
Performance on the baseline exercise test, both treadmill and bicycle is described in Tables 2 and 3 . Three hundred and nineteen patients were assessed on the treadmill and 289 on the bicycle. Total exercise time was less (mean 416 s vs 648 s), and angina more common on treadmill (76% vs 64%).
Only 537 patients (88%) had analysable ST segment monitoring tapes at baseline: 50% snowed evidence of transient ischaemia. Of those with ischaemic changes, 60% had only silent episodes, 10% painful episodes, and 30% both silent and painful episodes ( Table 4) .
Effects of treatment on resting heart rate
and blood pressure Table 5 shows the effects of treatment on the sitting and standing heart rate and blood pressures. Whereas atenolol and the combination caused a significant fall in heart rate (/"<001), nifedipine SR was associated with a slight increase in heart rate. All three treatments caused 
Effects of treatment on exercise test variables
Treadmill exercise Table 6 details the mean changes from baseline in time to pain, total exercise time, time to 1 mm ST segment depression, and maximal ST segment depression. Changes from baseline were highly significant for all Table 5 Changes with treatment in heart rates and blood pressures variables and all treatments at 6 weeks postrandomization, and there was no statistically significant difference among the treatments for any of the variables during either treatment assessment phase.
Bicycle exercise
As with the treadmill exercise group, changes from baseline were highly statistically significant for all variables and all treatments at 6 weeks following randomization (Table 7) . Furthermore there were no statistically significant differences among the treatments for any of the variables.
Survival analysis of exercise test variables
Estimated survival curves for the three treatment groups at 6 weeks post-randomization for both time to pain and time to 1 mm ST segment depression, using treadmill exercise testing and bicycle, exercise showed no significant differences among the three treatment groups.
Effects of treatment on frequency and duration of ambulatory ischaemia
The distribution of patients in each of the three treatment groups with respect to the presence or absence of episodes of ischaemia before and after 6 weeks of randomized treatment are shown in Table 8 . The effect of each treatment can be assessed by the asymmetry in the 2x2 tables. For instance, on atenolol, 71 patients had no evidence of ischaemia either before randomization or following 6 weeks of treatment, 45 patients having ischaemic changes during both (13 3) 146-5 (15 6) 0-74 (0 08) 82 138-8 (17-9) 78-5 (17-3) 162-7 (17-6) 0-76 (010) assessment phases. A further 44 patients had transient ischaemic changes before, but not following 6 weeks of atenolol, and 19 patients without transient ischaemia at baseline had such changes on therapy. The imbalance was highly statistically significant for all treatments; however, again there was no difference between the three treatment groups. Restricting attention only to those patients who had transient ischaemic changes at baseline, the relative frequencies of such patients who were free of ischaemia after 6 weeks of treatment (atenolol 44/89: nifedipine SR 40/87: combination 35/80) did not reveal any statistically significant differences. Also, the numbers of patients with ischaemia were similar for the three treatment groups, when assessing either the change in the total number of episodes or the total duration of ischaemic episodes.
Discussion
The TIBET study has provided an opportunity to assess the effects of standard therapeutic agents, both alone and in combination, on ischaemic activity during exercise testing and during daily activities in a large cohort of stable angina patients attending cardiac outpatients who were not considered to require revascularization. Such patients represent the large majority of angina patients being treated in Europe. Many relatively smallscale studies have reported on the anti-anginal and anti-ischaemic effects of the various agents used in this study, at least one reporting apparently superior anti-ischaemic effects of beta-adrenergic blocking agents when compared with calcium channel blocking agents' 121 . However, the present study shows that, in mildly symptomatic patients, a medium-term acting calcium channel blocking agent or a long-acting betaadrenergic blocking agent confer similar benefits in terms of increasing exercise duration on treadmill or bicycle ergometry or reduction of the total ischaemic burden.
The pathophysiological mechanisms of ischaemia are undoubtedly complex. Thus both agents used in this study would be expected to alter the mechanisms of myocardial oxygen supply/demand in beneficial ways, calcium antagonists primarily by coronary vasodilatation and afterload reduction, and beta-blockers by chronotropic control and reduction in myocardial wall tension'
131
. It is possible that previous reports showing more effective anti-ischaemic activity of beta-blockers when compared with dihydropyridine calcium channel blocking agents resulted from the study of 'more severe' stable angina patients, where smaller incremental increases in heart rate might have predisposed to myocardial ischaemia' 14 ' 151 , and where the recognized tendency to reflex tachycardia from the use of dihydropyridine agents' 161 might have to some extent negated their coronary vasodilating and afterload-reducing effects. In this study, resting heart rate after 6 weeks of therapy was reduced by 21% in the group receiving atenolol whereas it increased by 4% in those on nifedipine SR. Resting systolic blood pressure was reduced similarly (9%) by both agents. These findings would suggest that the importance of tight chronotropic control may be of less importance in patients with mild stable angina, perhaps reflecting a lower degree of severity of underlying coronary artery disease.
There appeared to be no significant benefit in terms of exercise testing on treadmill or bicycle ergometry or in reduction of the total ischaemic burden from the combination of the two agents, when compared with each agent alone; in spite of the fact that resting heart rate and systolic blood pressure after 6 weeks of combination therapy were reduced by 19% and 15% respectively; and despite the widely held belief that the combination of an agent with chronotropic control and myocardial relaxant properties with one with powerful coronary vasodilating and afterload-reducing activity should be beneficial 117] . There has been much conflicting evidence in the literature about the benefits or otherwise of combination therapy for the treatment of angina. However, from the ischaemia viewpoint there is much evidence in support of no significant further benefit from the addition of a second agent with different mechanisms of action' 18 ' 191 . This study supports that conclusion. The decision to add a second agent for further ischaemia reduction (rather than for symptom reduction) in patients with mild symptoms may therefore be inappropriate. The present study also suggests that in patients with persisting angina despite monotherapy combination therapy may not necessarily provide further symptomatic improvement 
Potential limitations of study
Because patients included for study were not required to have angiographically demonstrated coronary artery disease, it is possible that some of the study group did not have coronary disease. Against this, all patients had symptoms suggestive of angina which required attendance at cardiac outpatients and the administration of routine anti-anginal medications, and all patients had an ischaemic response to exercise. In addition, 50% of patients had evidence of transient ischaemic change during their daily lives while on placebo; this figure is representative of that quoted in other studies which assessed the frequency of transient ischaemia in patients with stable coronary disease 120 " 21 '. The fact that different exercise protocols were used in the study could have resulted in different outcomes. However, this study shows that both treadmill exercise testing and bicycle ergometry are equally effective in demonstrating the modification of ischaemic activity with the different therapeutic interventions used. This observation confirms that both forms of exercise assessment are useful when investigating the effects of therapeutic agents. In addition, the frequency of ischaemic activity during daily life was similar in patients included in the study on the basis of either exercise protocol.
Although the 'parallel group' structure of the study makes it impossible to state definitively that addition of a second agent in the patients randomized to either atenolol or nifedipine SR alone would not have resulted in further benefit in terms of ischaemia reduction, it is clear that the combination was no more effective than either agent alone when comparing the placebo and 6 week post-randomization data for each group.
Clinical implications of study findings
In patients with mild stable angina considered suitable for inclusion in a long-term prognostic study of the effects of medical therapy, and where a short placebo phase was incorporated, a slow release calcium channel blocking agent administered twice a day as monotherapy was as effective as a long-acting beta-adrenergic blocking agent given twice a day as monotherapy in terms of modification of the total ischaemic burden. Furthermore, there appears to be no additive benefit from combining these agents. This final observation raises questions about the best approach to the management of the patient who is receiving a calcium antagonist or a beta-blocker and who continues to demonstrate evidence of transient ischaemic activity. Should one add a second agent with different mechanisms of action, or should one decide on more aggressive management on the basis of 'failed medical therapy'? The evidence from this study suggests that the 'knee-jerk' reaction of adding a second or indeed a third agent at outpatients in the hope of achieving better ischaemia control might not be a particularly practical or beneficial one. In conclusion, if the patient is symptomatically controlled, the decision to add further agents should be based on the knowledge that such a course of action will lead to improved prognostic outcome: to date there is no evidence that this is the case.
